Electronic Nose Detects Pneumonia in Critically Ill Patients

(Philadelphia, PA) According to a team of researchers from University of Pennsylvania School of Medicine, an electronic nose - a relatively new version of a sensor previously used in the food, wine and perfume industries - can quickly and accurately diagnose pneumonia in critically ill, mechanically ventilated patients. The results will be presented at the CHEST 2002 Annual Meeting Tuesday, November 5th in San Diego.

"We wanted to further explore using the e-nose after the exciting results of an initial study we conducted back in 1997 with only 20 patients," said C. William Hanson, III, MD, professor of Anesthesia, Surgery and Internal Medicine, and lead author of the study. When it comes to lower pulmonary infections, especially in critically ill patients, time is of the essence for disease control. "Rather than waiting two to three days for the results of a bacterial culture or relying on chest X-rays which aren't always accurate, the e-nose can give us a head start toward a proper diagnoses. We could avoid over-prescribing powerful antibiotics which are usually given to patients while we're waiting for their test results, even though we don't know if they actually need them," adds Hanson.

In the current study, 415 mechanically ventilated, critical care patients were screened for the presence of ventilator associated pneumonia (VAP) using a clinical pneumonia score (CPIS). Patients with high CPIS scores were enrolled in the study as well as control patients who had no evidence of pneumonia. An exhaled breath sample was taken from each patient directly from the expiratory limb of the ventilator circuit into an electronic nose made by Cyrano Sciences, Pasadena, CA. This differs from the original study where breath samples were collected in plastic bags from the ventilators of intubated intensive care patients and then fed into a different electronic nose.

The e-nose contains an array of sensors consisting of carbon-black/polymer composites. The patient's exhaled breath gas was passed over these sensors which interact with volatile molecules to produce unique patterns that are displayed in two-dimensional "maps," or dot patterns on a computer screen. The results were analyzed using pattern recognition algorithms and assessed for a correlation between the actual CPIS scores and the one predicted by the nose. Hanson and his colleagues found that the nose made clear distinctions between the patients who were infected and those who were not.

"The data show good correlation between the actual scores and those predicted by the data from the e-nose sensor," said Hanson. "Furthermore, this study suggests that the commercial electronic nose, as is, would be reasonably successful in predicting ventilator associated pneumonia. It would be even more suited to the task if the sensor array could be customized." Preliminary data also suggests that the e-nose may be able to distinguish between pneumonias caused by different bacterial infections.

Cyrano Sciences, Inc., donated a "Cyranose" electronic nose for use in this study.

# # #


Editor's Note: Dr. Hanson does not have any financial ties with Cyrano Sciences, Inc., and will be available at the CHEST 2002 Annual Meeting and by phone for comment.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Share This Page: